^BOSTON, Dec. November 31, 2023 (GLOBE NEWSWIRE) — Novotech, (https://novotech-
cro.com/reports/gall-bladder-cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD-REPORT&utm_content=GBC) the leading Asian-
Pacific-focused biotech CRO with global execution capabilities
today has the latest report on the global clinical trials landscape
Published in 2023 on the topic of metastatic breast cancer.
Novotech’s team of research analysts provides these expert reports on a monthly basis
available completely free of charge. These reports provide up-to-date insights into the
global activity of clinical trials and show in which regions the
highest study volumes have been recorded and what factors are behind them
Trends stand. They address the hurdles that biotech companies face
are confronted with certain therapeutic areas and discuss future ones
Therapy paths and investment trends.
The report Metastatic Breast Cancer – Global Clinical Trial Landscape 2023
shows that there have been over 1,000 clinical trials worldwide since 2018. Besides that
The report states:?Of the 2.3 million breast cancer cases worldwide
0.67 million identified as metastatic breast cancer, with 45% on
Asia, 35% in Western regions and 20% in other regions.”
Download the report here (https://novotech-
cro.com/reports/metastatic-breast-cancer-global-clinical-trial-landscape-
2023?utm_source=MBC+PR&utm_medium=MBC+PR&utm_campaign=MBC+PR)
The report found that?significant differences in mortality depending on
Race and region exist, with higher rates among African Americans, Asians and
Pacific Islanders, while Caucasians have comparatively lower rates
exhibit”.
Metastatic breast cancer, also known as stage IV breast cancer, occurs
occurs when cancer cells spread from the breast to other parts of the body.
Despite advances in early detection and treatment, 20-30% develop
of people initially diagnosed with breast cancer
metastatic breast cancer, which has a 5-year survival rate of 30%
represents a challenge.
The report analyzed global trial data and found:
* The Asia Pacific (APAC) region accounts for over 35% of these
Studies lead, led by mainland China, South Korea and Australia.
* The United States and Europe together accounted for more than half of the
Studies on metastatic breast cancer, with Spain and France
played a key role in these regions.
* The Rest of the World (ROW) accounted for approximately 10% of global studies
metastatic breast cancer.
* The APAC region in particular performed well in recruiting studies
efficient and pointed compared to Europe and the United States
shorter lead times and faster recruitment rates.
The report examined current and future treatment options and
noted that doctors usually treat metastatic breast cancer
systemic medications such as chemotherapy, hormone therapy, targeted therapies
and use immunotherapy.
He also emphasized that the approval of Enhertu for HER2-poor breast cancer in the
Year 2022 represents a milestone for a subgroup of patients
There is hope and the strategy of personalized medicine for more precise and
more effective therapies for metastatic breast cancer.
Novotech employs more than 3,000 people in 25 countries
34 branches, including in the USA, Greater China, South Korea,
Australia, New Zealand and Europe.
The CRO offers biotechnology companies a unique and unparalleled experience
Offering early to late phase contract research services
the USA and Europe, with a focus on the Asia-Pacific region
is where the company has a good reputation in terms of implementation
high-quality accelerated clinical trials. The commitment of the
Company for collaboration is reflected in the 50 Leading Sites
Partnership agreements it has signed in the last three years.
About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-
cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD REPORT&utm_content=GBC)
Founded in 1997, Novotech is a global clinical
Full-service contract research organization (CRO) focused on
Collaboration with biotech companies focused on development
of advanced and novel therapeutics at every stage.
Recognized for its industry-leading contributions, Novotech has numerous
Received prestigious awards including the CRO Leadership Award
2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and
since 2006 the Asia-Pacific Contract Research Organization Company of the Year
Award.
The company offers a full range of services including
Laboratories, Phase I facilities, drug development consulting and
regulatory expertise, and has experience with over 5,000 clinical
Projects, including phase I to IV clinical trials and
Bioequivalence studies. With a presence in 34 locations and a dedicated
With a team of more than 3,000 professionals worldwide, Novotech is a trusted one
strategic end-to-end partner of choice.
For more information or to speak to an expert team member,
visit www.Novotech-CRO.com (http://www.novotech-cro.com/)
A photo accompanying this announcement is available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f517434-
9cee-438f-803b-7cb4db080bb3
°